Non-Alcoholic Fatty Liver Disease and Vascular Disease

Author(s): Roberta Forlano, Benjamin H. Mullish, Rooshi Nathwani, Ameet Dhar, Mark R. Thursz, Pinelopi Manousou*

Journal Name: Current Vascular Pharmacology

Volume 19 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver disease worldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD is cardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. It is globally projected that NAFLD will become increasingly prevalent, especially among children and younger adults. As such, even within the next few years, NAFLD will contribute considerably to the overall CVD burden.

In this review, we discuss the role of NAFLD as an emerging risk factor for CVD. In particular, this article aims to provide an overview of pathological drivers of vascular damage in patients with NAFLD. Moreover, the impact of NAFLD on the development, severity and the progression of subclinical and clinical CVD will be discussed. Finally, the review illustrates current and potential future perspectives to screen for CVD in this high-risk population.

Keywords: Non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular risk, endothelial dysfunction, atherosclerosis, obesity.

[1]
Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016; 64(5): 1577-86.
[http://dx.doi.org/10.1002/hep.28785] [PMID: 27543837]
[2]
Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28(1): 27-38.
[http://dx.doi.org/10.1161/ATVBAHA.107.147538] [PMID: 17690317]
[3]
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6): 1388-402.
[http://dx.doi.org/10.1016/j.jhep.2015.11.004] [PMID: 27062661]
[4]
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology 2018; 67(1): 328-57.
[http://dx.doi.org/10.1002/hep.29367] [PMID: 28714183]
[5]
Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61(5): 1547-54.
[http://dx.doi.org/10.1002/hep.27368] [PMID: 25125077]
[6]
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149(2): 389-97. e10
[7]
Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology 2018; 67(5): 1726-36.
[http://dx.doi.org/10.1002/hep.29546] [PMID: 28941364]
[8]
Mullish BH, Forlano R, Manousou P, Mikhailidis DP. Non-alcoholic fatty liver disease and cardiovascular risk: an update. Expert Rev Gastroenterol Hepatol 2018; 12(12): 1175-7.
[http://dx.doi.org/10.1080/17474124.2018.1533117] [PMID: 30791787]
[9]
Laslett LJ, Alagona P Jr, Clark BA III, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 2012; 60(25)(Suppl.): S1-S49.
[http://dx.doi.org/10.1016/j.jacc.2012.11.002] [PMID: 23257320]
[10]
Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017; 70(1): 1-25.
[http://dx.doi.org/10.1016/j.jacc.2017.04.052] [PMID: 28527533]
[11]
Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol 2018; 15(4): 230-40.
[http://dx.doi.org/10.1038/nrcardio.2017.154] [PMID: 29022571]
[12]
Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of sudden cardiac death among children and young adults. N Engl J Med 2016; 374(25): 2441-52.
[http://dx.doi.org/10.1056/NEJMoa1510687] [PMID: 27332903]
[13]
Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011; 58(12): 1254-61.
[http://dx.doi.org/10.1016/j.jacc.2011.01.049] [PMID: 21903060]
[14]
Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2014; 384(9945): 766-81.
[http://dx.doi.org/10.1016/S0140-6736(14)60460-8] [PMID: 24880830]
[15]
Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9•1 million participants. Lancet 2011; 377(9765): 557-67.
[http://dx.doi.org/10.1016/S0140-6736(10)62037-5] [PMID: 21295846]
[16]
Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008; 93(11)(Suppl. 1): S9-S30.
[http://dx.doi.org/10.1210/jc.2008-1595] [PMID: 18987276]
[17]
Swinburn B, Vandevijvere S. WHO report on ending childhood obesity echoes earlier recommendations. Public Health Nutr 2016; 19(1): 1-2.
[http://dx.doi.org/10.1017/S1368980015003663] [PMID: 26745231]
[18]
Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes 2008; 32(9): 1431-7.
[http://dx.doi.org/10.1038/ijo.2008.102] [PMID: 18607383]
[19]
Popkin BM, Conde W, Hou N, Monteiro C. Is there a lag globally in overweight trends for children compared with adults? Obesity (Silver Spring) 2006; 14(10): 1846-53.
[http://dx.doi.org/10.1038/oby.2006.213] [PMID: 17062816]
[20]
de Onis M, Blössner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr 2010; 92(5): 1257-64.
[http://dx.doi.org/10.3945/ajcn.2010.29786] [PMID: 20861173]
[21]
Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018; 69(4): 896-904.
[http://dx.doi.org/10.1016/j.jhep.2018.05.036] [PMID: 29886156]
[22]
Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(47): 8263-76.
[http://dx.doi.org/10.3748/wjg.v23.i47.8263] [PMID: 29307986]
[23]
Nobili V, Day C. Childhood NAFLD: a ticking time-bomb? Gut 2009; 58(11): 1442.
[http://dx.doi.org/10.1136/gut.2009.184465] [PMID: 19834114]
[24]
Anderson LM, Reilly EE, Schaumberg K, Dmochowski S, Anderson DA. Contributions of mindful eating, intuitive eating, and restraint to BMI, disordered eating, and meal consumption in college students. Eat Weight Disord 2016; 21(1): 83-90.
[http://dx.doi.org/10.1007/s40519-015-0210-3] [PMID: 26243300]
[25]
Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol 2016; 65(2): 425-43.
[http://dx.doi.org/10.1016/j.jhep.2016.04.005] [PMID: 27091791]
[26]
Sitia S, Tomasoni L, Atzeni F, et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010; 9(12): 830-4.
[http://dx.doi.org/10.1016/j.autrev.2010.07.016] [PMID: 20678595]
[27]
Lu B, Zhou J, Waring ME, Parker DR, Eaton CB. Abdominal obesity and peripheral vascular disease in men and women: a comparison of waist-to-thigh ratio and waist circumference as measures of abdominal obesity. Atherosclerosis 2010; 208(1): 253-7.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.06.027] [PMID: 19656509]
[28]
Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care 2001; 4(6): 499-502.
[http://dx.doi.org/10.1097/00075197-200111000-00006] [PMID: 11706283]
[29]
Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007; 133(2): 496-506.
[http://dx.doi.org/10.1053/j.gastro.2007.04.068] [PMID: 17681171]
[30]
Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012; 55(5): 1389-97.
[http://dx.doi.org/10.1002/hep.25539] [PMID: 22183689]
[31]
Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 2006; 6(3): 177-81.
[http://dx.doi.org/10.1007/s11892-006-0031-x] [PMID: 16898568]
[32]
Siddiqui MS, Fuchs M, Idowu MO, Luketic VA, Boyett S, Sargeant C, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. 2015.
[http://dx.doi.org/10.1016/j.cgh.2014.10.008]
[33]
Gambino R, Bugianesi E, Rosso C, et al. Different serum free fatty acid profiles in NAFLD Subjects and healthy controls after oral fat load. Int J Mol Sci 2016; 17(4): 479.
[http://dx.doi.org/10.3390/ijms17040479] [PMID: 27043543]
[34]
Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab 2011; 22(9): 353-63.
[http://dx.doi.org/10.1016/j.tem.2011.04.007] [PMID: 21616678]
[35]
Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89(6): 2548-56.
[http://dx.doi.org/10.1210/jc.2004-0395] [PMID: 15181022]
[36]
Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res 2000; 8(9): 673-5.
[http://dx.doi.org/10.1038/oby.2000.86] [PMID: 11225716]
[37]
Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95(5): 2409-15.
[http://dx.doi.org/10.1172/JCI117936] [PMID: 7738205]
[38]
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010; 90(1): 207-58.
[http://dx.doi.org/10.1152/physrev.00015.2009] [PMID: 20086077]
[39]
Schönfeld P, Wojtczak L. Fatty acids as modulators of the cellular production of reactive oxygen species. Free Radic Biol Med 2008; 45(3): 231-41.
[http://dx.doi.org/10.1016/j.freeradbiomed.2008.04.029] [PMID: 18482593]
[40]
Schönfeld P, Wojtczak L. Fatty acids decrease mitochondrial generation of reactive oxygen species at the reverse electron transport but increase it at the forward transport. Biochim Biophys Acta 2007; 1767(8): 1032-40.
[http://dx.doi.org/10.1016/j.bbabio.2007.04.005] [PMID: 17588527]
[41]
Maschirow L, Khalaf K, Al-Aubaidy HA, Jelinek HF. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes--Biomarkers as a possible tool for early disease detection for rural screening. Clin Biochem 2015; 48(9): 581-5.
[http://dx.doi.org/10.1016/j.clinbiochem.2015.02.015] [PMID: 25753569]
[42]
Craige SM, Kant S, Keaney JF Jr. Reactive oxygen species in endothelial function - from disease to adaptation. Circ Julation journal : official journal of the Japanese Circulation Society 2015; 79(6): 1145-55.
[43]
Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res 2014; 114(1): 214-26.
[http://dx.doi.org/10.1161/CIRCRESAHA.114.302355] [PMID: 24385514]
[44]
Paneni F, Cosentino F. Advanced glycation endproducts and plaque instability: a link beyond diabetes. Eur Heart J 2014; 35(17): 1095-7.
[http://dx.doi.org/10.1093/eurheartj/eht454] [PMID: 24179075]
[45]
Paneni F, Costantino S, Volpe M, Lüscher TF, Cosentino F. Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. Atherosclerosis 2013; 230(2): 191-7.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.07.003] [PMID: 24075743]
[46]
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107(9): 1058-70.
[http://dx.doi.org/10.1161/CIRCRESAHA.110.223545] [PMID: 21030723]
[47]
Banarjee R, Sharma A, Bai S, Deshmukh A, Kulkarni M. Proteomic study of endothelial dysfunction induced by AGEs and its possible role in diabetic cardiovascular complications. J Proteomics 2018; 187: 69-79.
[http://dx.doi.org/10.1016/j.jprot.2018.06.009] [PMID: 29935336]
[48]
Di Minno MN, Tufano A, Rusolillo A, Di Minno G, Tarantino G. High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol 2010; 16(48): 6119-22.
[http://dx.doi.org/10.3748/wjg.v16.i48.6119] [PMID: 21182227]
[49]
Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietilainen KH, et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver international : official journal of the International Association for the Study of the Liver 2011; 31(2): 176-83.
[50]
Bilgir O, Bilgir F, Bozkaya G, Calan M. Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease. 2014.
[http://dx.doi.org/10.1097/MBC.0000000000000009]
[51]
Verrijken A, Beckers S, Francque S, et al. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity (Silver Spring) 2013; 21(10): 2138-45.
[http://dx.doi.org/10.1002/oby.20366] [PMID: 23512881]
[52]
Barrera F, George J. Prothrombotic factors and nonalcoholic fatty liver disease: an additional link to cardiovascular risk? Hepatology 2014; 59(1): 16-8.
[http://dx.doi.org/10.1002/hep.26588] [PMID: 23787943]
[53]
Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46(4): 352-6.
[http://dx.doi.org/10.1038/ng.2901] [PMID: 24531328]
[54]
Scott E, Anstee QM. Genetics of alcoholic liver disease and non-alcoholic steatohepatitis. Clin Med (Lond) 2018; 18(Suppl. 2): s54-9.
[http://dx.doi.org/10.7861/clinmedicine.18-2-s54] [PMID: 29700094]
[55]
Kahali B, Liu YL, Daly AK, Day CP, Anstee QM, Speliotes EK. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? Gastroenterology 2015; 148(4): 679-84.
[http://dx.doi.org/10.1053/j.gastro.2015.01.038] [PMID: 25639710]
[56]
Vita JA, Loscalzo J. Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium. Circulation 2002; 106(2): 164-6.
[http://dx.doi.org/10.1161/01.CIR.0000023452.26135.34] [PMID: 12105150]
[57]
Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115(10): 1285-95.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.652859] [PMID: 17353456]
[58]
Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vas-odilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002; 39(2): 257-65.
[http://dx.doi.org/10.1016/S0735-1097(01)01746-6] [PMID: 11788217]
[59]
Kajikawa M, Maruhashi T, Hida E, et al. Combination of flow-mediated vasodilation and nitroglycerine-induced vasodilation is more effective for prediction of cardiovascular events. Hypertension 2016; 67(5): 1045-52.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.06839] [PMID: 26975705]
[60]
Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005; 26(1): 65-9.
[http://dx.doi.org/10.1093/eurheartj/ehi001] [PMID: 15615801]
[61]
Suzuki T, Hirata K, Elkind MS, et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the northern Manhattan study (NOMAS). Am Heart J 2008; 156(2): 405-10.
[http://dx.doi.org/10.1016/j.ahj.2008.02.022] [PMID: 18657678]
[62]
Roquer J, Segura T, Serena J, Castillo J. Endothelial dysfunction, vascular disease and stroke: the ARTICO study. Cerebrovasc Dis 2009; 27(Suppl. 1): 25-37.
[http://dx.doi.org/10.1159/000200439] [PMID: 19342831]
[63]
Chen PL, Wang PY, Sheu WH, et al. Changes of brachial flow-mediated vasodilation in different ischemic stroke subtypes. Neurology 2006; 67(6): 1056-8.
[http://dx.doi.org/10.1212/01.wnl.0000237526.32692.67] [PMID: 17000977]
[64]
Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42(2): 473-80.
[http://dx.doi.org/10.1002/hep.20781] [PMID: 15981216]
[65]
Mohammadi A, Sedani HH, Ghasemi-Rad M. Evaluation of carotid intima-media thickness and flow-mediated dilatation in middle-aged patients with nonalcoholic fatty liver disease. Vasc Health Risk Manag 2011; 7: 661-5.
[PMID: 22140316]
[66]
Colak Y, Senates E, Yesil A, et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013; 43(1): 100-7.
[http://dx.doi.org/10.1007/s12020-012-9712-1] [PMID: 22661277]
[67]
Persico M, Masarone M, Damato A, et al. Non-alcoholic fatty liver disease and eNOS dysfunction in humans. BMC Gastroenterol 2017; 17(1): 35.
[http://dx.doi.org/10.1186/s12876-017-0592-y] [PMID: 28264657]
[68]
Cetindağlı I, Kara M, Tanoglu A, et al. Evaluation of endothelial dysfunction in patients with nonalcoholic fatty liver disease: Association of selenoprotein P with carotid intima-media thickness and endothelium-dependent vasodilation. Clin Res Hepatol Gastroenterol 2017; 41(5): 516-24.
[http://dx.doi.org/10.1016/j.clinre.2017.01.005] [PMID: 28760353]
[69]
Johnson CP, Baugh R, Wilson CA, Burns J. Age related changes in the tunica media of the vertebral artery: implications for the assessment of vessels injured by trauma. J Clin Pathol 2001; 54(2): 139-45.
[http://dx.doi.org/10.1136/jcp.54.2.139] [PMID: 11215283]
[70]
Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam study. Circulation 2006; 113(5): 657-63.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.555235] [PMID: 16461838]
[71]
Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hy-pertensive patients. Hypertension 2001; 37(5): 1236-41.
[http://dx.doi.org/10.1161/01.HYP.37.5.1236] [PMID: 11358934]
[72]
Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013; 230(2): 258-67.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.07.052] [PMID: 24075754]
[73]
Villela-Nogueira CA, Leite NC, Cardoso CR, Salles GF. NAFLD and increased aortic stiffness: parallel or common physiopathological mechanisms? Int J Mol Sci 2016; 17(4)E460
[http://dx.doi.org/10.3390/ijms17040460] [PMID: 27104526]
[74]
Lee YJ, Shim JY, Moon BS, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012; 57(1): 196-203.
[http://dx.doi.org/10.1007/s10620-011-1819-3] [PMID: 21750929]
[75]
Li N, Zhang GW, Zhang JR, et al. Non-alcoholic fatty liver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis 2015; 25(2): 218-23.
[http://dx.doi.org/10.1016/j.numecd.2014.10.002] [PMID: 25456154]
[76]
Salvi P, Ruffini R, Agnoletti D, et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 2010; 28(8): 1699-707.
[http://dx.doi.org/10.1097/HJH.0b013e32833a7de6] [PMID: 20467324]
[77]
Sunbul M, Agirbasli M, Durmus E, et al. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis 2014; 237(2): 490-3.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.10.004] [PMID: 25463079]
[78]
Cobble M, Bale B. Carotid intima-media thickness: knowledge and application to everyday practice. Postgrad Med 2010; 122(1): 10-8.
[http://dx.doi.org/10.3810/pgm.2010.01.2091] [PMID: 20107284]
[79]
Kabra A, Neri L, Weiner H, Khalil Y, Matsumura ME. Carotid intima-media thickness assessment in refinement of the Framingham Risk Score: can it predict ST-elevation myocardial infarction? A pilot study. Echocardiography 2013; 30(10): 1209-13.
[http://dx.doi.org/10.1111/echo.12272] [PMID: 23937519]
[80]
Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012; 308(8): 796-803.
[http://dx.doi.org/10.1001/jama.2012.9630] [PMID: 22910757]
[81]
Zheng J, Zhou Y, Zhang K, et al. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old. BMC Cardiovasc Disord 2018; 18(1): 147.
[http://dx.doi.org/10.1186/s12872-018-0877-2] [PMID: 30012085]
[82]
Chen Y, Xu M, Wang T, et al. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis 2015; 241(1): 145-50.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.002] [PMID: 25988358]
[83]
Colak Y, Karabay CY, Tuncer I, et al. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2012; 24(6): 613-8.
[http://dx.doi.org/10.1097/MEG.0b013e3283513f19] [PMID: 22495402]
[84]
Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40(12): 1461-5.
[http://dx.doi.org/10.1038/ng.257] [PMID: 18820647]
[85]
Di Costanzo A, D’Erasmo L, Polimeni L, et al. Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of met-abolically- versus genetically-driven excess fat hepatic storage. Atherosclerosis 2017; 257: 232-9.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.12.018] [PMID: 28027788]
[86]
Pacifico L, Chiesa C, Anania C, et al. Nonalcoholic fatty liver disease and the heart in children and adolescents. World J Gastroenterol 2014; 20(27): 9055-71.
[PMID: 25083079]
[87]
Pisto P, Santaniemi M, Bloigu R, Ukkola O, Kesäniemi YA. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open 2014; 4(3)e004973
[http://dx.doi.org/10.1136/bmjopen-2014-004973] [PMID: 24650811]
[88]
Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Askling J, et al. Cardiovascular risk factors in non-alcoholic fatty liver disease. 2019.
[http://dx.doi.org/10.1111/liv.13973]
[89]
Wong DT, Leung MC, Das R, et al. Intracoronary ECG during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction predicts microvascular obstruction and infarct size. Int J Cardiol 2013; 165(1): 61-6.
[http://dx.doi.org/10.1016/j.ijcard.2011.07.078] [PMID: 21875755]
[90]
Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60(12): 1721-7.
[http://dx.doi.org/10.1136/gut.2011.242016] [PMID: 21602530]
[91]
Puchner SB, Lu MT, Mayrhofer T, et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology 2015; 274(3): 693-701.
[http://dx.doi.org/10.1148/radiol.14140933] [PMID: 25369449]
[92]
Sinn DH, Kang D, Chang Y, et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut 2017; 66(2): 323-9.
[http://dx.doi.org/10.1136/gutjnl-2016-311854] [PMID: 27599521]
[93]
Keskin M, Hayıroğlu MI, Uzun AO, Güvenç TS, Şahin S, Kozan Ö. Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2017; 120(10): 1720-6.
[http://dx.doi.org/10.1016/j.amjcard.2017.07.107] [PMID: 28867124]
[94]
Henriques JP, Zijlstra F, van ’t Hof AW, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 2003; 107(16): 2115-9.
[http://dx.doi.org/10.1161/01.CIR.0000065221.06430.ED] [PMID: 12695301]
[95]
Emre A, Terzi S, Celiker E, et al. Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for st-segment elevation myocardial infarction. Am J Cardiol 2015; 116(12): 1810-4.
[http://dx.doi.org/10.1016/j.amjcard.2015.09.021] [PMID: 26506122]
[96]
Lauridsen BK, Stender S, Kristensen TS, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J 2018; 39(5): 385-93.
[http://dx.doi.org/10.1093/eurheartj/ehx662] [PMID: 29228164]
[97]
Ying I, Saposnik G, Vermeulen MJ, Leung A, Ray JG. Nonalcoholic fatty liver disease and acute ischemic stroke. Epidemiology 2011; 22(1): 129-30.
[http://dx.doi.org/10.1097/EDE.0b013e3181feb50a] [PMID: 21150361]
[98]
Pickhardt PJ, Hahn L, Muñoz del Rio A, Park SH, Reeder SB, Said A. Natural history of hepatic steatosis: observed outcomes for sub-sequent liver and cardiovascular complications. AJR Am J Roentgenol 2014; 202(4): 752-8.
[http://dx.doi.org/10.2214/AJR.13.11367] [PMID: 24660702]
[99]
Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla VM. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr 2017; 11(Suppl. 1): S209-16.
[http://dx.doi.org/10.1016/j.dsx.2016.12.033] [PMID: 28017631]
[100]
Kim G, Kim KJ, Rhee Y, Lim SK. Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. PLoS One 2017; 12(7)e0182202
[http://dx.doi.org/10.1371/journal.pone.0182202] [PMID: 28759632]
[101]
Li H, Hu B, Wei L, et al. Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions. Eur J Neurol 2018; 25(3): 577-e34.
[http://dx.doi.org/10.1111/ene.13556] [PMID: 29281159]
[102]
Hu J, Xu Y, He Z, et al. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget 2017; 9(2): 2752-60.
[PMID: 29416808]
[103]
Tziomalos K, Giampatzis V, Bouziana SD, et al. Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome. World J Hepatol 2013; 5(11): 621-6.
[http://dx.doi.org/10.4254/wjh.v5.i11.621] [PMID: 24303090]
[104]
Zhang Y, Li P, Miao M, et al. Nonalcoholic fatty liver disease is associated with increased atrial fibrillation risk in an elderly Chinese population: a cross-sectional study. BioMed Res Int 2018; 20185628749
[http://dx.doi.org/10.1155/2018/5628749] [PMID: 30112401]
[105]
Whitsett M, Wilcox J, Yang A, Zhao L, Rinella M, VanWagner LB. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. Liver Int 2019; 39(5): 933-40.
[http://dx.doi.org/10.1111/liv.14018] [PMID: 30536602]
[106]
Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010; 5(12): 2166-71.
[http://dx.doi.org/10.2215/CJN.05050610] [PMID: 20724519]
[107]
Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51(11): 1947-53.
[http://dx.doi.org/10.1007/s00125-008-1135-4] [PMID: 18762907]
[108]
Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008; 19(8): 1564-70.
[http://dx.doi.org/10.1681/ASN.2007101155] [PMID: 18385424]
[109]
Yeung MW, Wong GL, Choi KC, et al. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes.J Hepatol 2017; S0168-8278(17): 32334-6.
[PMID: 28989092]
[110]
Glen J, Floros L, Day C, Pryke R. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ 2016; 354: i4428.
[http://dx.doi.org/10.1136/bmj.i4428] [PMID: 27605111]
[111]
Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017; 67(6): 1265-73.
[http://dx.doi.org/10.1016/j.jhep.2017.07.027] [PMID: 28803953]
[112]
Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis Severity as a Determinant of Cause-specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. 2018.
[http://dx.doi.org/10.1053/j.gastro.2018.04.034]
[113]
Abeles RD, Mullish BH, Forlano R, et al. Derivation and validation of a cardiovascular risk score for prediction of major acute cardio-vascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. Aliment Pharmacol Ther 2019; 49(8): 1077-85.
[http://dx.doi.org/10.1111/apt.15192] [PMID: 30836450]
[114]
Targher G, Lippi G. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019; 49(8): 1092-3.
[http://dx.doi.org/10.1111/apt.15208] [PMID: 30920047]
[115]
Mullish BH, Forlano R, Abeles RD, Thursz MR, Manousou P. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non-alcoholic fatty liver disease - authors’ reply. Aliment Pharmacol Ther 2019; 49(8): 1093-4.
[http://dx.doi.org/10.1111/apt.15215] [PMID: 30920045]
[116]
Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham heart study. Arterioscler Thromb Vasc Biol 2007; 27(1): 127-33.
[http://dx.doi.org/10.1161/01.ATV.0000251993.20372.40] [PMID: 17095717]
[117]
Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med 2016; 4(24): 481.
[http://dx.doi.org/10.21037/atm.2016.12.27] [PMID: 28149843]
[118]
Wannamethee SG, Lennon L, Shaper AG. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008; 201(1): 168-75.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.01.019] [PMID: 18378241]
[119]
Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010; 52(3): 1156-61.
[http://dx.doi.org/10.1002/hep.23789] [PMID: 20658466]
[120]
Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009; 50(5): 1403-11.
[http://dx.doi.org/10.1002/hep.23135] [PMID: 19670414]
[121]
Jaruvongvanich V, Wijarnpreecha K, Ungprasert P. The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study. Clin Res Hepatol Gastroenterol 2017; 41(6): 629-34.
[http://dx.doi.org/10.1016/j.clinre.2017.03.010] [PMID: 28716600]
[122]
Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013; 19(8): 1219-29.
[http://dx.doi.org/10.3748/wjg.v19.i8.1219] [PMID: 23482703]
[123]
Kim SU, Song D, Heo JH, et al. Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. Atherosclerosis 2017; 260: 156-62.
[http://dx.doi.org/10.1016/j.atherosclerosis.2017.02.005] [PMID: 28222857]
[124]
Simon TG, Corey KE, Cannon CP, et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol 2018; 270: 245-52.
[http://dx.doi.org/10.1016/j.ijcard.2018.05.087] [PMID: 29903515]
[125]
Boursier J, Vergniol J, Guillet A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol 2016; 65(3): 570-8.
[http://dx.doi.org/10.1016/j.jhep.2016.04.023] [PMID: 27151181]
[126]
Park HE, Lee H, Choi SY, Kwak MS, Yang JI, Yim JY, et al. Usefulness of controlled attenuation parameter for detecting increased arterial stiffness in general population. 2018.
[http://dx.doi.org/10.1016/j.dld.2018.04.027]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2021
Published on: 17 March, 2020
Page: [269 - 279]
Pages: 11
DOI: 10.2174/1570161118666200318103001
Price: $65

Article Metrics

PDF: 29
HTML: 3